Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Galbraith

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cell Death and Differentiation|October 25, 2019
EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteinsLeah Fitzsimmons, Rachel Cartlidge, Catherine Chang, et al.
Cancer Research|May 14, 2021
SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate CancerRafael S Martinez, Mark J Salji, Linda Rushworth, et al.
Nature|October 28, 2016
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer modelsAndrás Kotschy, Zoltán Szlavik, James Murray, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cell Death and Differentiation|October 25, 2019
EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteinsLeah Fitzsimmons, Rachel Cartlidge, Catherine Chang, et al.
Cancer Research|May 14, 2021
SLFN5 Regulates LAT1-Mediated mTOR Activation in Castration-Resistant Prostate CancerRafael S Martinez, Mark J Salji, Linda Rushworth, et al.
Nature|October 28, 2016
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer modelsAndrás Kotschy, Zoltán Szlavik, James Murray, et al.
Pageof 2